Modified MRC assessment and FEV1.0 can predict frequent acute exacerbation of COPD: An observational prospective cohort study at a single-center in Japan

Asai, Nobuhiro; Ohkuni, Yoshihiro; Ohashi, Wataru; Kaneko, Norihiro

doi:10.1016/j.rmed.2023.107218

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous clinical predictors of acute exacerbation risk in COPD have been assessed, including low body mass index (BMI) ( 7 ), deteriorating lung function ( 8 ), increased COPD assessment test (CAT) scores ( 9 ), modified Medical Research Council (mMRC) dyspnea scale scores ( 10 ), and elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) ( 11 ). However, predicting COPD-FE risk and understanding its underlying pathogenic mechanisms remains challenging due to the heterogeneity and complexity of COPD.…”

Section: Introductionmentioning

confidence: 99%

Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and ‘frequent exacerbator’ phenotype

Ding,

Wang,

et al. 2024

Mol Med Rep

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and ‘frequent exacerbator’ phenotype

Ding,

Wang,

et al. 2024

Mol Med Rep

View full text Add to dashboard Cite

Epidemiological study of respiratory syncytial virus infection in adults during the pandemic of COVID-19

Asai,

Shibata,

Yamada

et al. 2024

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

COPD Pathogenesis and Alterations in the Oral, Lung, and Gut Microbiomes

Asai,

Ohkuni,

Kato

et al. 2024

Microbiology Research

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a respiratory and systemic disease affecting more than 300 million people globally every year, and it also becomes a substantial economic burden. COPD is commonly comorbid with various underlying diseases such as cancer, cardiovascular diseases, cerebrovascular diseases, diabetes mellitus, osteoporosis, etc. It has been shown that statins can improve a significant decline in pulmonary function among COPD patients due to their pleiomorphic effect. Some systematic reviews also reported that statins reduced the risk of COPD-related events such as cancer and cardiovascular events, eventually resulting in more favorable outcomes than for non-statin user COPD patients. However, the physiological mechanism is still elucidated. Recently, it has been reported that statins influence the gut microbial composition with increased relative abundance of Akkermansia muciniphila and Faecalibacterium prausnitzii and act with pleiomorphic effects such as anti-inflammatory and anti-cancer effects through modulating gut dysbiosis. We described this review to focus on whether statins can be a useful preventive option for COPD.

show abstract

Modified MRC assessment and FEV1.0 can predict frequent acute exacerbation of COPD: An observational prospective cohort study at a single-center in Japan

Cited by 3 publications

References 21 publications

Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and ‘frequent exacerbator’ phenotype

Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and ‘frequent exacerbator’ phenotype

Epidemiological study of respiratory syncytial virus infection in adults during the pandemic of COVID-19

COPD Pathogenesis and Alterations in the Oral, Lung, and Gut Microbiomes

Contact Info

Product

Resources

About